

VENA KAVA SÜPERIOR SENDROMU YÖNETİMİNDE PULMONER YAKLAŞIMLAR

27.
BÖLÜM

Esen SAYIN GÜLENSOY¹

GİRİŞ

Vena kava süperior sendromu (VKSS), vena kava süperior (VKS) boyunca kan akışının kısmen veya tamamen engellenmesinden kaynaklanan klinik belirti ve semptomların oluşturduğu bir tablodur. İlk bildirilen vaka, 1757 yılında İskoç bir doktor olan William Hunter tarafından sifilitik aortitli bir hastada tanımlanmıştır (1).

VKSS mediastinal malignitelerin önemli bir sekeldir ve hasta için ciddi klinik sıkıntırlara neden olabilir. VKSS, laringeal veya serebral ödem ile ilişkiliyse tıbbi bir acil durumdur (2).

ANATOMİ

Sağ ve sol brakiocefalik venlerin birleşmesiyle oluşan vena kava süperior toplam venöz dönüşün yaklaşık üçte birini sağlayarak baş, boyun, üst extremiteler ve göğüsün üst kısmından gelen kanı kalbe taşıır. Orta mediastende bulunur. Sternum, trakea, sağ bronş, aort, pulmoner arter, perihiler ve paratrakeal lenf düğümleri gibi nispeten sert yapılarla çevrilidir. Sağ ve sol brakiocefalik venlerin birleşim yerinden sağ atriyuma doğru 6-8 cm. kadar uzanır. Orta ve ön mediastenin sağında yer alan kitleler VKS'ye bası yaparak vena kava süperior sendromuna neden olabilir. Aorta veya trakeaya kıyasla ince duvarı ve düşük venöz basıncı nedeniyle VKS obstrükte olacak mediastinal vasküler yapılar arasında ilkidir (3,4).

ETİYOLOJİ

Antibiyotikler yaygınlaşmadan önce, bulaşıcı etiyolojiler VKSS'nin yaygın bir nedeniydi. Spesifik olarak, sifilise bağlı aort anevrizmaları sık görüldürdü (5). Ancak

¹ Dr. Öğr. Üyesi, Ufuk Üniversitesi Tıp Fakültesi Göğüs Hastalıkları Anabilim Dalı esen_sayin@hotmail.com ORCID iD: 0000-0002-0154-7775

KAYNAKLAR

1. Hunter W, Johnston W. The history of an aneurysm of the aorta, with some remarks on aneurysms in general. London: William Johnston; 1757
2. Christopher Straka, James Ying, FengMing Kong et al. Review of evolving etiologies, implications and treatment strategies for the superior vena cava syndrome, 2016;5229
3. Armstrong BA, Perez CA, Simpson JR, Hederman MA. Role of irradiation in the management of superior vena cava syndrome. *Int J Radiat Oncol Biol Phys.* 1987 Apr; 13 (4):531-9.
4. Howard MR III, J Bayne S, Spencer BG et al. Normal Venous Anatomy and Collateral Pathways in Upper Extremity Venous Thrombosis. *Radiographics* 1992;12:527-534
5. Schechter MM (1954) The superior vena cava syndrome. *Am J Med Sci* 227:46-56
6. Rice TW, Rodriguez RM, Light RW. The superior vena cava syndrome: clinical characteristics and evolving etiology. *Medicine (Baltimore)* 2006; 85:37.
7. Yellin A, Rosen A, Reichert N, Lieberman Y. Superior vena cava syndrome. The myth--the facts. *Am Rev Respir Dis* 1990; 141:1114.
8. Schraufnagel DE, Hill R, Leech JA, Pare JA. Superior vena caval obstruction. Is it a medical emergency? *Am J Med.* 1981 Jun; 70 (6):1169-74.
9. Markman M. Diagnosis and management of superior vena cava syndrome. *Cleve Clin J Med* 1999; 66:59.
10. Salsali M, Cliffton EE. Superior vena caval obstruction in carcinoma of lung. *N Y State J Med* 1969; 69:2875.
11. Rowell NP, Gleeson FV. Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus: a systematic review. *Clin Oncol (R Coll Radiol)* 2002; 14:338.
12. Dombernowsky P, Hansen HH. Combination chemotherapy in the management of superior vena caval obstruction in small-cell anaplastic carcinoma of the lung. *Acta Med Scand* 1978; 204:513.
13. Spiro SG, Shah S, Harper PG, et al. Treatment of obstruction of the superior vena cava by combination chemotherapy with and without irradiation in small-cell carcinoma of the bronchus. *Thorax* 1983; 38:501.
14. Sculier JP, Evans WK, Feld R, et al. Superior vena caval obstruction syndrome in small cell lung cancer. *Cancer* 1986; 57:847.
15. Urban T, Lebeau B, Chastang C, et al. Superior vena cava syndrome in small-cell lung cancer. *Arch Intern Med* 1993; 153:384.
16. Würschmidt F, Büinemann H, Heilmann HP. Small cell lung cancer with and without superior vena cava syndrome: a multivariate analysis of prognostic factors in 408 cases. *Int J Radiat Oncol Biol Phys* 1995; 33:77.
17. Perez-Soler R, McLaughlin P, Velasquez WS, et al. Clinical features and results of management of superior vena cava syndrome secondary to lymphoma. *J Clin Oncol* 1984; 2:260.
18. Presswala RG, Hiranandani NL. Pleural effusion and superior vena cava canal syndrome in Hodgkin's disease. *J Indian Med Assoc* 1965; 45:502.
19. Cheng S. Superior vena cava syndrome: a contemporary review of a historic disease. *Cardiol Rev* 2009; 17:16
20. Mineo TC, Ambrogi V, Nofroni I, Pistolese C, Mediastinoscopy in superior vena cava obstruction: analysis of 80 consecutive patients. *Ann Thorac Surg* 1999;68:223-226
21. D'Angio GJ, Mitus A, Evans AE,: The superior mediastinal syndrome in children with cancer. *AJR Am J Roentgenol.* 1965;93:537-44
22. Yu JB, Wilson LD, Detterbeck FC. Superior vena cava syndrome--a proposed classification system and algorithm for management. *J Thorac Oncol* 2008; 3:811.
23. Kim HJ, Kim HS, Chung SH, CT diagnosis of superior vena cava syndrome: importance of collateral vessels. *AJR Am J Roentgenol* 1993;161:539-542
24. Uberoi R Quality assurance guidelines for superior vena cava stenting in malignant disease. *Cardiovasc Intervent Radiol* 2006;29:319-322

25. Lacout A, Marcy PY, Thariat J, Lacombe P, El Hajjam M Radio-anatomy of the superior vena cava syndrome and therapeutic orientations. *Diagn Interv Imaging* 2012;93:569–577.
26. Cosmo L, Haponik EF, Darlak JJ, Summer WR. Neoplastic superior vena caval obstruction: diagnosis with percutaneous needle aspiration. *Am J Med Sci* 1987; 293:99.
27. Engel IA, Auh YH, Rubenstein WA, et al. CT diagnosis of mediastinal and thoracic inlet venous obstruction. *AJR Am J Roentgenol* 1983; 141:521.
28. William S, Howard J, Stephen E, Lee CC et al. Superior vena cava obstruction: a venographic classification. *AJR Am J Roentgenol.* 1987 Feb;148(2):259-62.).
29. Qanadli SD, El Hajjam M, Bruckert F, et al. Helical CT phlebography of the superior vena cava: diagnosis and evaluation of venous obstruction. *AJR Am J Roentgenol* 1999; 172:1327.
30. Abner A. Approach to the patient who presents with superior vena cava obstruction. *Chest*. 1993 Apr. 103 (4 Suppl):394S-397S
31. Wilson LD, Detterbeck FC, Yahalom J. Clinical practice. Superior vena cava syndrome with malignant causes. *N Engl J Med* 2007; 356:1862.
32. Loeffler JS, Leopold KA, Recht A, et al. Emergency prebiopsy radiation for mediastinal masses: impact on subsequent pathologic diagnosis and outcome. *J Clin Oncol* 1986; 4:716.
33. Flounders JA. Oncology emergency modules: superior vena cava syndrome. *Oncol Nurs Forum*. 2003 Jul-Aug. 30 (4):E84-90
34. Levitt SH, Jones TK Jr, Kilpatrick SJ Jr, Bogardus CR Jr. Treatment of malignant superior vena caval obstruction. A randomized study. *Cancer* 1969; 24:447.
35. Kvale PA, Selecky PA, Prakash UB, American College of Chest Physicians. Palliative care in lung cancer: ACCP evidence-based clinical practice guidelines (2nd edition). *Chest* 2007; 132:368S.
36. Sculier JP, Evans WK, Feld R, et al. Superior vena caval obstruction syndrome in small cell lung cancer. *Cancer* 1986; 57:847.
37. Nagata T, Makutani S, Uchida H, et al. Follow-up results of 71 patients undergoing metallic stent placement for the treatment of a malignant obstruction of the superior vena cava. *Cardiovasc Interv Radiol* 2007; 30:959.
38. Martin M, Baumgartner I, Kolb M, et al. Fatal pericardial tamponade after Wallstent implantation for malignant superior vena cava syndrome. *J Endovasc Ther* 2002; 9:680.
39. Fagedet D, Thony F, Timsit JF, et al. Endovascular treatment of malignant superior vena cava syndrome: results and predictive factors of clinical efficacy. *Cardiovasc Interv Radiol* 2013; 36:140.